My HPRA: Register

The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie

Equasym XL 40 mg modified-release capsules, hard

Takeda Pharmaceuticals International AG Ireland BranchPA23211/001/004

Main Information

Trade NameEquasym XL 40 mg modified-release capsules, hard

Active SubstancesMethylphenidate hydrochloride

Dosage FormModified-release capsule, hard

Licence HolderTakeda Pharmaceuticals International AG Ireland Branch

Licence NumberPA23211/001/004

Group Information

ATC CodeN06BA Centrally acting sympathomimetics
N06BA04 methylphenidate

Status

License statusAuthorised

Licence Issued08/02/2013

Legal statusProduct subject to prescription which may not be renewed (A)

Supply StatusSupply through pharmacies only

Advertising StatusAdvertising to healthcare professionals only

Conditions of LicenceMedicinal product subject to restricted medical prescription (see Summary of Product Characteristics, 4.2). This product contains a substance listed in schedule 2 to the Misuse of Drugs Regulations 2017.

Marketing StatusNot marketed